Cencora, Inc. (NYSE:COR) Stake Boosted by Unique Wealth LLC

Unique Wealth LLC grew its stake in shares of Cencora, Inc. (NYSE:COR) by 7.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,385 shares of the company’s stock after acquiring an additional 92 shares during the period. Unique Wealth LLC’s holdings in Cencora were worth $311,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of COR. Concord Wealth Partners acquired a new position in Cencora during the 3rd quarter worth $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora during the second quarter valued at about $36,000. Ashton Thomas Securities LLC acquired a new position in shares of Cencora during the third quarter valued at about $41,000. Fairscale Capital LLC acquired a new position in shares of Cencora during the second quarter valued at about $54,000. Finally, Modus Advisors LLC acquired a new position in shares of Cencora during the fourth quarter valued at about $54,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 0.0 %

COR opened at $236.10 on Tuesday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm has a market capitalization of $45.63 billion, a price-to-earnings ratio of 31.44, a PEG ratio of 1.54 and a beta of 0.49. The company’s 50 day moving average price is $237.82 and its two-hundred day moving average price is $233.54.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is presently 29.29%.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock worth $22,862,734 in the last quarter. Company insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COR. Wells Fargo & Company dropped their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Leerink Partners decreased their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.